Giulio Cassanello
Overview
Explore the profile of Giulio Cassanello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn J, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39893244
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-cell lymphoma (LBCL). This study compares patterns of disease relapse and progression across...
2.
Luan D, DeWolf S, Fei T, Raj S, Shah G, Lareau C, et al.
Blood Cancer Discov
. 2024 Dec;
6(2):119-130.
PMID: 39666878
This study reveals differences in IR patterns after CAR-T therapy in patients with large B-cell lymphoma, with early NK cell recovery emerging as a key predictor of survival. These findings...
3.
Valtis Y, Devlin S, Shouval R, Rejeski K, Corona M, Luna de Abia A, et al.
Blood Adv
. 2024 Oct;
9(1):151-161.
PMID: 39471490
Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of lymphoma, yet many patients relapse. Several prognostic markers have been associated with CAR T-cell outcomes, such as tumor burden,...
4.
Cassanello G, Drill E, Rivas-Delgado A, Okwali M, Isgor I, Caron P, et al.
Haematologica
. 2024 Sep;
110(2):439-447.
PMID: 39234863
The combination of rituximab and lenalidomide (R-len) stands as an established treatment for relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). However, the reproducibility of clinical trial results in routine clinical practice...
5.
Lorenc R, Shouval R, Flynn J, Devlin S, Saldia A, Luna de Abia A, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):990-1000.
PMID: 38972512
Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T...
6.
Cederquist G, Schefflein J, Devlin S, Shah G, Shouval R, Hubbeling H, et al.
Blood Adv
. 2024 Jun;
8(19):5192-5199.
PMID: 38861344
Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable. Bridging radiotherapy (BRT) is used for extracranial...
7.
Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek A, et al.
Am J Hematol
. 2024 May;
99(8):1624-1627.
PMID: 38769663
No abstract available.
8.
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
Cassanello G, Luna de Abia A, Falchi L
Oncoimmunology
. 2024 Mar;
13(1):2321648.
PMID: 38445082
Immunotherapy has shaped the treatment approach to diffuse large B-cell lymphoma (DLBCL), with rituximab leading to remarkable improvements in outcomes for both relapsed and treatment-naïve patients. Recently, groundbreaking immunotherapies like...
9.
Fattizzo B, Gurnari C, Cassanello G, Bortolotti M, Awada H, Giammarco S, et al.
Leukemia
. 2023 Oct;
37(12):2479-2485.
PMID: 37794100
Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric...
10.
Fattizzo B, Pasquale R, Croci G, Pettine L, Cassanello G, Barcellini W
Blood Transfus
. 2023 Sep;
22(3):266-272.
PMID: 37677091
No abstract available.